Tests LVIVO-TaVec200 treatment in people with relapsed or refractory multiple myeloma
Tests the LVIVO-TaVec200 product in adults with multiple myeloma that has returned or not responded.
Plain-language title generated from the registry record
Registry title: A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
Key facts
- Where
- Nanjing, Shanghai, Xi'an, Xuzhou, and Zhengzhou, ChinaSee the 5 sites
- Phase
- Early phase 1
Where in China
- The First Affiliated Hospital with Nanjing Medical UniversityNanjing, ChinaTaking people
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaNot yet recruiting
- The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaNot yet recruiting
- The affiliated hospital of xuzhou medical universityXuzhou, ChinaNot yet recruiting
- Henan Cancer HospitalZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Trial code
- NCT07294625
- Record updated
- 19 December 2025
- Original description
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.Read full original descriptionShow less
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec200 Product in the Treatment of Relapsed/Refractory Multiple Myeloma
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.
Inclusion: Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up; Age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Has measurable lesions; Relapsed and/or refractory multiple myeloma; Life expectancy≥ 3 months; Clinical laboratory values meet screening visit criteria; Adequate organ function.
Exclusion: Prior antitumor therapy with insufficient washout period ; Prior treatment targeting GPRC5D; Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab); Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator); Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study.